Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were noted in sex distribution, comorbidities (hypertension, diabetes), or other laboratory parameters (lipid profile, GFR, 25‐hydroxyvitamin D; p > 0.05).

Source: Demographic and Clinical Characteristics of Participants. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this cross‐sectional study, 243 patients with PD and 90 age‐ and sex‐matched healthy controls (HCs) were enrolled.

Source: Abstract.

Based on motor symptoms, PD patients were further divided into three subtypes: tremor‐dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND).

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients

Cross-sectional study · Brain and Behavior · 2026

Original publication title

Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients

Meilin Gui; Lixia Qin; Lingling Lv; Jinduo Huang; Shenglan Hu; Kexin Chen; Xing Wang; Yiwen Zhou; Beisha Tang; Hainan Zhang; Chunyu Wang

© 2026 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Cognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint‐category analysis, patients in the PIGD‐low‐irisin group had higher odds of concurrent cognitive impairment than those in the TD‐high‐irisin group.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Cognitive impairment is a common non‐motor symptom of Parkinson's disease (PD) that markedly reduces patients’ quality of life. Given the clinical heterogeneity of PD‐related cognitive impairment (PDCI), further clarification of clinical and circulating biological factors associated with cognitive status may help improve our understanding of cognitive dysfunction in PD.

Source: Introduction

Abstract: What methods does the paper describe?

In this cross‐sectional study, 243 patients with PD and 90 age‐ and sex‐matched healthy controls (HCs) were enrolled. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and patients with PD were classified into the PD with cognitive impairment (PDCI) and PD without cognitive impairment (PDNCI) groups. Based on motor symptoms, PD patients were further divided into three subtypes: tremor‐dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND). Group comparisons and logistic regression analyses were performed to examine factors associated with cognitive impairment.

Source: Methods

Abstract: Results

Serum irisin levels did not differ significantly between patients with PD and healthy controls (p = 0.478). Compared with PDNCI patients, those with PDCI had lower serum irisin levels. Among motor subtypes, the PIGD group showed a higher prevalence of cognitive impairment (68.8% vs. 46.2%, p < 0.001) and significantly lower irisin levels compared with the TD group [3.25 (2.62 to 4.14) vs. 4.12 (3.42 to 5.07) µg/mL, p < 0.001]. Serum irisin levels were weakly but positively associated with memory performance, and this association remained significant after FDR correction across the five cognitive domains (r = 0.194, FDR‐adjusted p = 0.010).

Compared with patients in the TD: high irisin group, those in the PIGD: low irisin group had higher odds of concurrent cognitive impairment (OR = 6.065, 95% CI: 2.974 to 18.638, p = 0.002).

Source: Results

Abstract: Conclusion

Cognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint‐category analysis, patients in the PIGD‐low‐irisin group had higher odds of concurrent cognitive impairment than those in the TD‐high‐irisin group.

Source: Conclusion
Authors’ abstract

ABSTRACT

Introduction

Cognitive impairment is a common non‐motor symptom of Parkinson's disease (PD) that markedly reduces patients’ quality of life. Given the clinical heterogeneity of PD‐related cognitive impairment (PDCI), further clarification of clinical and circulating biological factors associated with cognitive status may help improve our understanding of cognitive dysfunction in PD.

Methods

In this cross‐sectional study, 243 patients with PD and 90 age‐ and sex‐matched healthy controls (HCs) were enrolled. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and patients with PD were classified into the PD with cognitive impairment (PDCI) and PD without cognitive impairment (PDNCI) groups. Based on motor symptoms, PD patients were further divided into three subtypes: tremor‐dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND). Group comparisons and logistic regression analyses were performed to examine factors associated with cognitive impairment.

Results

Serum irisin levels did not differ significantly between patients with PD and healthy controls (p = 0.478). Compared with PDNCI patients, those with PDCI had lower serum irisin levels. Among motor subtypes, the PIGD group showed a higher prevalence of cognitive impairment (68.8% vs. 46.2%, p < 0.001) and significantly lower irisin levels compared with the TD group [3.25 (2.62 to 4.14) vs. 4.12 (3.42 to 5.07) µg/mL, p < 0.001]. Serum irisin levels were weakly but positively associated with memory performance, and this association remained significant after FDR correction across the five cognitive domains (r = 0.194, FDR‐adjusted p = 0.010).

Compared with patients in the TD: high irisin group, those in the PIGD: low irisin group had higher odds of concurrent cognitive impairment (OR = 6.065, 95% CI: 2.974 to 18.638, p = 0.002).

Conclusion

Cognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint‐category analysis, patients in the PIGD‐low‐irisin group had higher odds of concurrent cognitive impairment than those in the TD‐high‐irisin group.

Publication and source details

Original title: Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients

Meilin Gui; Lixia Qin; Lingling Lv; Jinduo Huang; Shenglan Hu; Kexin Chen; Xing Wang; Yiwen Zhou; Beisha Tang; Hainan Zhang; Chunyu Wang

Brain and Behavior · 2026

© 2026 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. National Natural Science Foundation of China10.13039/501100001809 8247127782101342 National Science Foundation of Hunan Province 2024JJ5471

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:35:44.215575+00:00

DOI: 10.1002/brb3.71848 · PMC13686351